Testing Hydronidone for liver fibrosis safety
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests an experimental pill called Hydronidone for people with liver fibrosis (scarring) caused by chronic hepatitis B or fatty liver disease. It aims to see if the drug is safe and may help slow or reverse liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have liver fibrosis (scarring) from chronic hepatitis B or fatty liver disease.
- Your liver is not too severely damaged — certain blood tests (bilirubin, liver enzymes) must be within a specific range.
- You have not had cancer (except for some minor skin or early-stage cancers) in the past 5 years.
- You have not used the medicine interferon in the last 3 months.
- You agree to use effective birth control if you could become pregnant or father a child, during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Hepalatide for people with chronic hepatitis D (a liver infection). You must already have hepatitis B and be on a stable antiviral for it. The study checks if Hepalatide can safely lower HDV levels.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This study tests how a drug called hydronidone is processed and removed from the body using a very small amount of radioactive labeling. It helps researchers understand how the drug works, so it may lead to better treatments for conditions like liver fibrosis.
This trial tests a single dose of the study drug hydroxynidone in people with different levels of kidney function, including healthy volunteers and those with kidney disease. The goal is to learn how the drug works in the body when kidneys are not working normally.
Hear when a new Chronic Hepatitis B With Hepatic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.